Fig 1: Impact of SG in DNA damage repair pathwaysCells were left untreated or pretreated with SG (10 μg/mL for 30 min/37°C, washed thrice with PBS) prior to treatment with ATRi berzosertib for all experiments.(A and B) Western blot analysis for DNA damage markers of lysates from cells pretreated with SG and treated with ATRi (1 μM) overnight. Densitometric quantitation was performed as detailed in the STAR Methods. Densitometric values of phosphorylated proteins relative to total proteins are further normalized to untreated (value of 1) for each cell line and shown below respective images. Values were rounded to two significant numbers. Representative of 3 biologically independent experiments.(C) Graphs show results from homologous recombination (HR) repair activity assay. After cells were pretreated with SG, they were cultured overnight in plain media and then transfected with HR reporter plasmids overnight, followed by treatment with ATRi or in plain media for 48 h prior to flow cytometric analysis for GFP expression. Mock transfection without plasmids were also performed as a control for transfection efficiency. Flow data was analyzed on Flowjo and plotted as histograms. Percent GFP-positive (GFP+ve) cells for histograms are shown under each range gate. This is representative of two experimental replicates.(D) Representative images of cells pretreated with SG, washed and incubated overnight with ATRi (1 μM) prior to co-staining for targets RPA1 (green foci) and Cyclin B1 (CCNB1, red). For reference, images of cell cycle phases as inferred from CCNB1 staining is given below image panels. The graph (middle panel) shows the mean ratio ±SD of RPA1+ve cells (>5 foci) to total cells (n = 100–300) from all sampled fields (n = 3–5 biological replicates) for each treatment. The stacked plot on the right show percent distribution of RPA1+ve cells across cell cycle phases as defined by staining pattern of nuclear CCNB1 from the sampled fields (n = 3–5 biological replicates per treatment). Representative of n = 2 biologically independent experiments. ∗∗p < 0.01, and ∗∗∗p < 0.001, ns, not significant. Scale bar is 20 μm.
Fig 2: Effect of SG and berzosertib on tumorigenicity and replication fork stability(A) PEO1 and PEO1-olaJR were pretreated with SG followed by ATRi (1 μM overnight prior to analyzing them for incorporated BrdU. Images show BrdU-positive (BrdU+ve) cells expressed as percentage of total cells (within boxes) against DNA quantity (PI) as determined by FlowJo software. Images are representative of 3 biologically independent experiments.(B) Graphs show stacked plots as fractions (as indicated by numbers) of total BrdU+ve cells derived from panel A distributed across G1, S or G2/M phases.(C) Immunofluorescent confocal microscopic analysis for RPA1 (green) and γH2AX-S139 (pink) of cells pretreated with SG (10μg/ml for 30 min at 37°C, washed 3 times with PBS) and then exposed to berzosertib (ATRi) (1 μM) overnight. Approximately 100–300 cells were analyzed over 3–5 sampled microscopic fields. Graphs show mean ± SD of % cells positive for RPA1 (>5 foci) or γH2AX foci (>15 foci) relative to total cells from each sampled field (n = 3–5 biological replicates). Statistical significance was determined with Student’s t test (p-values). Results are representative of 2 biologically independent experiments. Scale bar is 20 μm.(D) DNA fiber assays was performed as described in STAR Methods. About 200 DNA fibers were selected and the length of both red (IdU) and green (CldU) segments of each strand were measured using Fiji software. Representative strands are shown to the left. Graphs on the right show mean ± SD of the ratios of IdU/CldU from all strands (n = ∼200) per treatment using GraphPad prism. Statistical significance was determined with Student’s t test and represented as p-values, ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001, ns, not significant. Results are representative of 2 biologically independent experiments. Scale bar is 10 μm.
Supplier Page from Abcam for Alexa Fluor® 488 Anti-RPA70 antibody [EPR3472]